New findings support the use of radical prostatectomy (RP) for patients with high-risk localized prostate cancer (PCa), researchers concluded.
Dan Lewinshtein, MD, and collaborators at Virginia Mason Medical Center in Seattle studied 91 PCa patients with pathologic Gleason 8-10 disease. Sixty-two patients (68.9%) had stage T3 disease or higher and 48 (52.7%) had positive surgical margins. The median follow-up of these patients after RP was 8.2 years.
The predicted 10-year rates of biochemical recurrence-free survival, metastasis-free survival, and prostate cancer-specific survival were 59%, 88%, and 94%, respectively, according to an online report in Advances in Urology.
“We have demonstrated that cancer control is durable even 10 years after RP in those with pathologic Gleason 8-10 disease,” the authors concluded.
Additionally, classical predictors of outcomes—such as pathologic stage and surgical margin status—were not significantly associated with outcomes in the current study, the investigators noted.